UK Health Security Agency, London, 2025.
This report summarises England’s progress towards the World Health Organization (WHO) elimination targets for hepatitis C virus infection with data to end of 2023.
Aust Society for HIV, Viral Hep & Sexual Health Medicine (ASHM), Sydney, 2025.
The most recently available treatment data to June 2024, an assessment of ongoing trends from 2016 and more accurate geographic location for hepatitis C treatment.
Aust Society for HIV, Viral Hep & Sexual Health Medicine (ASHM), Sydney, 2025.
This report includes data regarding hepatitis B, as well as estimates of viral hepatitis testing and liver cancer. The most recent available estimates for prevalence, treatment and care of hepatitis B to the end of 2023, with testing data available to June of 2024 are presented.
American Assoc for the Study of Liver Diseases (AASLD), Alexandria, 2022.
Provides a brief overview including the discovery of the virus, clinical course, how to screen, prevalence and treatment.
Viruses ; Vol. 17, 3. MDPI, Basel, 2025.
Reports the positive impact of direct-acting antivirals on outcomes for people with hepatitis C. Highlights the need for ongoing monitoring for those at risk of liver cancer, screening for people at risk of infection or reinfection, ensuring safe medical procedures, needle and syringe provision and the need to continue working on the development of a vaccine.
Australian Journal of General Practice ; Vol. 52 (8). Royal Australian College of General Practitioners (RACGP), East Melbourne, 2023.
The diversity of risk factors and geographical origins of patients in the multicultural Australian populace highlights the need for routine testing for HDV in patients diagnosed with chronic hepatitis B (CHB). GPs have a pivotal role in the diagnosis of HDV and should, if possible, promptly refer patients to non-GP specialist physicians to consider HDV therapy.
Medical News Today, Bexhill-on-Sea, 2025.
People who used lipophilic (fat-soluble) statins like atorvastatin and simvastatin had the greatest outcomes and significantly reduced risk for liver cancer, according to a new study.
Journal of Clinical and Translational Hepatology ; Vol.13, 3. Xia & He Publishing, Wuhan, 2024.
Chronic hepatitis B (CHB) remains a significant global health challenge, and effective antiviral therapies are essential for long-term management. This study aimed to evaluate the real-world effectiveness and safety of tenofovir amibufenamide (TMF) in a cohort of patients with chronic hepatitis B (CHB). Found TMF is comparable to TDF in terms of CHB treatment effectiveness, with better renal safety and no impact on lipid levels.
Journal of Hepatology ; Vol. 82 (4). European Association for the Study of the Liver (EASL), Geneva, 2025.
Discusses the findings of recent studies into combining pegylated interferon with the newly approved bulevirtide. Combination therapy was effective at higher than the approved dose. Treatment strategies and ideal length of treatment remain unclear.
Journal of Clinical and Translational Hepatology ; Vol. 13 (3). Xia & He Publishing, Wuhan, 2024.
The quantitative effects of alcohol consumption on cirrhosis and hepatocellular carcinoma (HCC) in hepatitis B virus (HBV) infection are unknown. This study aimed to establish a dose-dependent model of alcohol consumption on the risks of cirrhosis and HCC. Findings: alcohol dose-dependently increases the risks of cirrhosis and HCC in patients with HBV infection, and patients with daily alcohol consumption of more than 12 g should be strictly monitored.
La Trobe University, Melbourne, 2025.
This research project aimed to generate new knowledge about the relationship between human rights and drug policy, and consider whether there are other methods beyond human rights for moving towards more humane and less punitive approaches to drug use, possession and supply.
International Journal of Drug Policy ; Vol. 137. Elsevier, London, 2025.
Findings highlight the need for advocacy towards legal reform and the creation of inclusive organisational cultures. Recognising and valuing the LLE of peer workers is essential for enhancing harm reduction initiatives and promoting the wellbeing of PWUDs.
Journal of Viral Hepatitis ; Vol. 32, 2. John Wiley and Son, Melbourne, 2025.
Reports on a systematic review of qualitative evidence from 28 studies to identify why hepatitis C screening and treatment programmes within prisons have lower uptake than those outside of prison despite the higher rate of viral hepatitis among people in prison. Makes recommendations to modify in-prison programmes to improve access.
Commonwealth of Australia, Canberra, 2025.
Highlights what the Commonwealth Government has delivered in 2024 and outlines its priorities for the next 12 months to contribute to achieving the goals of the National Agreement on Closing the Gap.
Close the Gap Campaign Alliance Group for Indigenous Equity, Phillip, ACT, 2025.
The Close the Gap Campaign annual reports, emphasising both the ongoing challenges and the tangible solutions needed to close the health and wellbeing gap for Aboriginal and Torres Strait Islander peoples. The 2025 report showcases how the closing the gap priority reform areas are being implemented to create lasting change.
For enquiries or feedback, please contact the librarian at Librarian@hepatitissa.asn.au.
| Address: | 3 Hackney Road Hackney SA 5069 |
| Phone: | (08) 8362 8443 |
| Fax: | (08) 8362 8559 |
| Email: | Librarian@hepatitissa.asn.au |
| Post: | PO Box 782 Kent Town SA 5071 |
Monday – Friday
9am to 5pm
Hepatitis SA is a non-profit, community-based organisation that provides information, education and support services to South Australians affected by hepatitis B and hepatitis C.